Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS followed by mFOLFOX6 vs mFOLFOX6 followed by IRIS in advanced colorectal cancer
NCT00316745Phase 3Suspended
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- Apr 2006
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tegafur, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (CRC), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Started Apr 2006; status: suspended.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00316745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00316745.